Amisha Singapuri

Apr 8, 2024 | nature.com | Claudia Efstathiou |Shona C Moore |Jose Nunag |Amisha Singapuri |Marco Sereno |Linzy Houchen-Wolloff | +12 more

AbstractOne in ten severe acute respiratory syndrome coronavirus 2 infections result in prolonged symptoms termed long coronavirus disease (COVID), yet disease phenotypes and mechanisms are poorly understood1. Here we profiled 368 plasma proteins in 657 participants ≥3 months following hospitalization. Of these, 426 had at least one long COVID symptom and 233 had fully recovered. Elevated markers of myeloid inflammation and complement activation were associated with long COVID.

Oct 16, 2023 | thelancet.com | S Byrne |Christopher E. Brightling |Rachael Evans |Amisha Singapuri

Key questions discussed at the PHOSP-COVID Scientific SummitThe PHOSP-COVID Scientific Summit included a review of progress and a discussion focused on four key questions pertaining to future research that were identified in advance of the summit. Question 1: How should we approach future pandemic research for long-term sequelae?

Aug 31, 2023 | nature.com | Maxime Taquet |Alex Horsley |Amisha Singapuri |Marco Sereno |Linzy Houchen-Wolloff |Neil J. Greening | +5 more

AbstractPost-COVID cognitive deficits, including ‘brain fog’, are clinically complex, with both objective and subjective components. They are common and debilitating, and can affect the ability to work, yet their biological underpinnings remain unknown. In this prospective cohort study of 1,837 adults hospitalized with COVID-19, we identified two distinct biomarker profiles measured during the acute admission, which predict cognitive outcomes 6 and 12 months after COVID-19.